Oncology Clinical Trials Market Size Worth USD 23.50 Billion by 2034 | CAGR: 5.17%

The oncology clinical trials market size is expected to reach USD 23.50 Billion by 2034, according to a new study by Polaris Market Research. The report “Oncology Clinical Trials Market Share, Size, Trends, Industry Analysis Report: By Cancer Type (Lung cancer, Breast cancer, Thyroid cancer), By Phase, By Study Design, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The oncology clinical trials market provides integrated solutions for pharmaceutical, biotechnology and research sectors. The market includes clinical trials across cancer types, phases, and study designs supporting drug development, drug delivery, regulatory approvals, and patient access to innovative therapies.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/oncology-clinical-trials-market/request-for-sample

Market growth is driven by rising global cancer prevalence, increasing investment in oncology drug development, and advancements in targeted and immunotherapy treatments.

Oncology Clinical Trials Market Report Highlights

• Based on cancer type, the lung cancer segment dominated in 2024, driven by high prevalence and strong adoption of targeted and immunotherapy trials.
• In terms of phase, the phase I segment dominated in 2024, fueled by early-stage safety and dosage studies for new oncology therapies.
• Based on study design, the interventional segment dominated in 2024 due to high adoption of experimental and controlled trials for novel therapies.
• North America dominated the global market in 2024, supported by advanced clinical research infrastructure and high cancer incidence.
• Asia Pacific is projected to record the fastest growth, driven by rising cancer prevalence and expanding healthcare access in emerging markets.
• Key players in the global market include Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., and Takeda Pharmaceutical Company Ltd.

Polaris Market Research has segmented the market report based on cancer type, phase, study design, and region:

By Cancer Type (Revenue, USD Billion, 2020–2034)

• Lung cancer
• Breast cancer
• Thyroid cancer
• Leukemia
• Liver cancer
• Skin cancer
• Lymphoma
• Pancreatic cancer
• Prostate cancer
• Colon & rectal cancer
• Urinary system cancer
• Other cancer

By Phase (Revenue, USD Billion, 2020–2034)

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design (Revenue, USD Billion, 2020–2034)

• Interventional
• Observational
• Expanded Access

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America